Bertis and Innoquest Diagnostics Sign a Strategic Partnership to Bring Bertis’ Technology to the Southeast Asian Market

-    Bertis signs a supply agreement with LifeStrands, an innovative clinical genomics company, to launch MASTOCHECK® testing in Thailand and the Philippines

-    High expectations for rapid adoption of MASTOCHECK®, driven by strong interest from local medical professionals and LifeStrands' extensive network

[Image] Innoquest Diagnostics & Bertis logo

On July 3, Bertis, a company specializing in proteomics-based precision medicine technology, led by CEOs Dong-young Noh and Seung-man Han, announced the signing of a strategic partnership agreement with Innoquest Diagnostics, the leading clinical diagnostics laboratory in Singapore.

Innoquest Diagnostics is a leading independent and internationally accredited diagnostics provider in Singapore. It is a subsidiary of Pathology Asia, one of Southeast Asia’s largest networks of independent laboratories. With operations across Singapore, Malaysia, Vietnam, the Philippines, Thailand, Indonesia, and Australia, Pathology Asia collectively serves a population of over 500 million. With its large-scale infrastructure and regional reach, the group is well-positioned as a key enabler of accessible, high-volume cancer screening throughout Southeast Asia. This partnership aims to establish the local testing infrastructure for Bertis’ proteomics-based blood test for early breast cancer detection, while laying the foundation for service expansion into new Asia-Pacific markets.

Under this strategic collaboration, Bertis will provide its mass spectrometry-based proteomic analysis technology, which powers its CHECK series of blood-based diagnostic tests, including MASTOCHECK® as well as additional pipeline tests targeting other cancers, such as pancreatic and ovarian cancer.

Innoquest Diagnostics will operate the test at its facilities and handle its distribution and commercialization in Singapore. This collaboration enables Bertis to establish a strong operational footprint to meet the growing demand for advanced diagnostic solutions. The two companies plan to sequentially expand the service through the Pathology Asia network of laboratories into other Southeast Asian countries including Indonesia, Malaysia, Thailand, Vietnam, the Philippines, Australia, and Hong Kong.

Through this partnership, Bertis aims to accelerate the localization and adoption of its cancer early detection technologies, further strengthening the global competitiveness of its proteomics-based precision diagnostic platform. Southeast Asia presents a significant unmet need for early cancer detection given high cancer incidence rates coupled with low screening coverage. Blood-based diagnostics such as MASTOCHECK® offer a compelling, accessible solution for this region.

Thomas Halusa, CEO of Innoquest Diagnostics, added, “We are excited to partner with Bertis to bring innovative, blood-based cancer screening tools to Singapore and the broader region. This collaboration aligns with our commitment to advancing accessible, science-led diagnostic solutions and reinforces our role as a region's partner of choice for global medical technology innovators.”

Seung-man Han, CEO of Bertis, stated, “This partnership reflects the trust and executional experience we’ve built in Singapore around proteomics technologies. More than just a distribution deal, it marks a strategic entry into the Southeast Asia cancer diagnostics market based on our proprietary technology. We hope that MASTOCHECK® and our broader portfolio of proteomics-based early detection solutions will make a meaningful contribution to improving cancer care across diverse healthcare systems.”